Edition:
United States

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.56USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
196,556
52-wk High
$8.37
52-wk Low
$0.65

Select another date:

Mon, Apr 9 2018

BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease

* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE

BRIEF-vTv Therapeutics Says Phase 1B Study Of TTP399 For The Treatment Of Type 1 Diabetes Completed

* VTV THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1B STUDY EVALUATING TTP399 FOR THE TREATMENT OF TYPE 1 DIABETES Source text for Eikon: Further company coverage:

BRIEF-VTV Therapeutics Reports Q4 Loss Per Share $0.44

* VTV THERAPEUTICS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-vTv Therapeutics Files For Stock Shelf Of Up To $250 Million

* VTV THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION – SEC FILING‍​ Source text for Eikon: (http://bit.ly/2EUHrux) Further company coverage:

BRIEF-Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement

* VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM

BRIEF-vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program

* VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM

BRIEF-VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes

* VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING

BRIEF-vTv Therapeutics reports Q3 GAAP loss per share of $0.38

* vTv Therapeutics reports third quarter 2017 financial and operational results

Select another date: